Literature DB >> 20805432

Does black ethnicity influence the development of stent thrombosis in the drug-eluting stent era?

Sara D Collins1, Rebecca Torguson, Michael A Gaglia, Gilles Lemesle, Asmir I Syed, Itsik Ben-Dor, Yanlin Li, Gabriel Maluenda, Kimberly Kaneshige, Zhenyi Xue, Kenneth M Kent, Augusto D Pichard, William O Suddath, Lowell F Satler, Ron Waksman.   

Abstract

BACKGROUND: It has been suggested that black race predicts stent thrombosis (ST) after drug-eluting stent implantation. Whether socioeconomic status or comorbid conditions confound the contribution of black race to the development of ST is unclear. METHODS AND
RESULTS: We compared 1594 black patients who underwent drug-eluting stent implantation with 5642 nonblack patients. Overall, 108 definite STs were reported. Multivariable Cox regression analysis was performed with adjustment for comorbidities, including median household income as a marker of socioeconomic status, to assess the impact that black race may have on the development of ST. On univariable analysis, black patients were younger (63.43±12.42 versus 65.15±12.59 years; P<0.001) and more likely to have a history of hypertension (89.8% versus 81.7%; P<0.001), diabetes mellitus (45.5% versus 30.8%; P<0.001), chronic renal insufficiency (19.2% versus 10.7%; P<0.001), and congestive heart failure (18.7% versus 13.1%; P<0.001). Clopidogrel compliance at the time of the ST event was higher in the black than in the nonblack population (87.5% versus 77.8%; P=0.068). After multivariable analysis, including adjustment for median income and clopidogrel compliance, black race emerged as a strong predictor of definite late ST.
CONCLUSIONS: Black race is an independent predictor of definite drug-eluting stent ST. Because clopidogrel compliance was higher in black patients and socioeconomic status was not associated with ST, further investigation into the potential mechanisms of this influence of race on ST must be pursued.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20805432     DOI: 10.1161/CIRCULATIONAHA.109.907998

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  10 in total

1.  Is it time to consider ethnicity in treatment guidelines?

Authors:  Bryony M Mearns
Journal:  Nat Rev Cardiol       Date:  2010-12       Impact factor: 32.419

2.  Capsule Commentary on Lafata et al., Medication Adherence Does Not Explain Black-White Differences in Cardiometabolic Risk Factor Control among Insured Patients with Diabetes.

Authors:  Ana M Palacio
Journal:  J Gen Intern Med       Date:  2016-02       Impact factor: 5.128

3.  "East asian paradox": challenge for the current antiplatelet strategy of "one-guideline-fits-all races" in acute coronary syndrome.

Authors:  Young-Hoon Jeong
Journal:  Curr Cardiol Rep       Date:  2014-05       Impact factor: 2.931

4.  Outcomes in Women and Minorities Compared With White Men 1 Year After Everolimus-Eluting Stent Implantation: Insights and Results From the PLATINUM Diversity and PROMUS Element Plus Post-Approval Study Pooled Analysis.

Authors:  Wayne Batchelor; David E Kandzari; Scott Davis; Luis Tami; John C Wang; Islam Othman; Osvaldo S Gigliotti; Amir Haghighat; Sarabjeet Singh; Mario Lopez; Gregory Giugliano; Phillip A Horwitz; Jaya Chandrasekhar; Paul Underwood; Craig A Thompson; Roxana Mehran
Journal:  JAMA Cardiol       Date:  2017-12-01       Impact factor: 14.676

5.  Differential Outcomes by Race and Ethnicity in Patients with Coronary Heart Disease: A Contemporary Review.

Authors:  Heidi Mochari-Greenberger; Lori Mosca
Journal:  Curr Cardiovasc Risk Rep       Date:  2015-05

6.  Race/ethnic disparities in risk factor control and survival in the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial.

Authors:  Nirat Beohar; Veronica V Sansing; Andrew M Davis; V S Srinivas; Tarek Helmy; Andrew D Althouse; Stephen B Thomas; Maria Mori Brooks
Journal:  Am J Cardiol       Date:  2013-08-01       Impact factor: 2.778

7.  Platelet reactivity in response to aspirin and ticagrelor in African-Americans and European-Americans.

Authors:  Margaret Infeld; Kevin A Friede; Tan Ru San; Holly J Knickerbocker; Geoffrey S Ginsburg; Thomas L Ortel; Deepak Voora
Journal:  J Thromb Thrombolysis       Date:  2020-11-06       Impact factor: 2.300

Review 8.  Ethnic Differences in Oral Antithrombotic Therapy.

Authors:  Haechan Cho; Jeehoon Kang; Hyo Soo Kim; Kyung Woo Park
Journal:  Korean Circ J       Date:  2020-08       Impact factor: 3.243

9.  Risk of Major Adverse Cardiovascular Events and Major Hemorrhage Among White and Black Patients Undergoing Percutaneous Coronary Intervention.

Authors:  Anping Cai; Chrisly Dillon; William B Hillegass; Mark Beasley; Brigitta C Brott; Vera A Bittner; Gilbert J Perry; Ganesh V Halade; Sumanth D Prabhu; Nita A Limdi
Journal:  J Am Heart Assoc       Date:  2019-11-08       Impact factor: 5.501

10.  Platelet function testing to predict hyporesponsiveness to clopidogrel in patients with chest pain seen in the emergency department.

Authors:  Rakesh K Sharma; Stephen W Erickson; Rohit Sharma; Donald J Voelker; Hanumanth K Reddy; Harvinder Dod; James D Marsh
Journal:  Vasc Health Risk Manag       Date:  2013-05-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.